Ipca Laboratories 将来の成長

Future 基準チェック /46

Ipca Laboratories利益と収益がそれぞれ年間30%と11.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に15% 29.8%なると予測されています。

主要情報

30.0%

収益成長率

29.8%

EPS成長率

Pharmaceuticals 収益成長	17.8%
収益成長率	11.8%
将来の株主資本利益率	15.0%
アナリストカバレッジ	Good
最終更新日	18 Nov 2024

今後の成長に関する最新情報

Recent updates

Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00

Nov 17

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Sep 10

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Jun 07

These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well

Sep 20

Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?

Aug 09

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Jun 08

How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?

Mar 26

Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?

Mar 13

Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently

Feb 28

Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Feb 23

Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?

Feb 11

Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?

Jan 30

The Ipca Laboratories (NSE:IPCALAB) Share Price Is Up 264% And Shareholders Are Boasting About It

Jan 15

業績と収益の成長予測

NSEI:IPCALAB - アナリストの将来予測と過去の財務データ ( )INR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2027	113,704	14,653	10,367	13,671	16
3/31/2026	101,565	11,681	8,497	12,462	17
3/31/2025	89,434	8,916	7,991	11,927	17
9/30/2024	85,343	6,612	8,977	14,414	N/A
6/30/2024	82,133	5,768	N/A	N/A	N/A
3/31/2024	77,059	5,474	5,341	9,447	N/A
12/31/2023	71,875	5,643	N/A	N/A	N/A
9/30/2023	66,806	4,922	2,612	6,767	N/A
6/30/2023	62,500	4,911	N/A	N/A	N/A
3/31/2023	62,481	4,713	3,113	8,058	N/A
12/31/2022	60,225	5,250	N/A	N/A	N/A
9/30/2022	59,070	6,142	2,398	7,616	N/A
6/30/2022	58,505	7,205	N/A	N/A	N/A
3/31/2022	58,305	8,841	3,771	8,561	N/A
12/31/2021	56,561	9,152	N/A	N/A	N/A
9/30/2021	56,355	9,837	3,728	8,554	N/A
6/30/2021	54,521	10,005	N/A	N/A	N/A
3/31/2021	54,207	11,400	7,286	10,901	N/A
12/31/2020	53,802	10,647	N/A	N/A	N/A
9/30/2020	51,833	9,968	7,371	10,767	N/A
6/30/2020	51,061	9,228	N/A	N/A	N/A
3/31/2020	46,499	6,063	2,641	5,704	N/A
12/31/2019	44,563	6,189	N/A	N/A	N/A
9/30/2019	42,496	5,804	2,877	5,181	N/A
6/30/2019	39,777	5,059	N/A	N/A	N/A
3/31/2019	37,750	4,448	3,205	5,010	N/A
3/31/2018	32,852	2,394	N/A	3,411	N/A
3/31/2017	31,562	1,945	N/A	2,819	N/A
3/31/2016	28,671	931	N/A	7,087	N/A
3/31/2015	31,444	2,542	N/A	4,682	N/A
3/31/2014	32,818	4,785	N/A	5,223	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IPCALABの予測収益成長率 (年間30% ) は貯蓄率 ( 6.7% ) を上回っています。

収益対市場: IPCALABの収益 ( 30% ) はIndian市場 ( 18% ) よりも速いペースで成長すると予測されています。

高成長収益: IPCALABの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: IPCALABの収益 ( 11.8% ) Indian市場 ( 10.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: IPCALABの収益 ( 11.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IPCALABの自己資本利益率は、3年後には低くなると予測されています ( 15 %)。

Ipca Laboratories 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Price target increased by 8.6% to ₹1,320

Price target increased by 9.1% to ₹1,097

Price target increased by 9.7% to ₹987

Price target decreased by 7.1% to ₹858

Consensus EPS estimates fall by 21%

Price target decreased to ₹1,067

Recent updates

Second quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat

Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00

Dividend of ₹2.00 announced

Ipca Laboratories Limited to Report Q2, 2025 Results on Nov 14, 2024

Ipca Laboratories Limited Announces Cessation of Manisha Premnath as Independent Director and Member of the Nomination & Remuneration Committee and Stakeholders Relationship Committee, Effective September 21, 2024

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Price target increased by 8.6% to ₹1,320

Ipca Laboratories Limited Approves Appointment of Vivek Shiralkar as an Independent Director

Upcoming dividend of ₹2.00 per share

Ipca Laboratories Limited to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Less than half of directors are independent

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Ipca Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Full year 2024 earnings released: EPS: ₹25.82 (vs ₹18.58 in FY 2023)

Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing

Ipca Laboratories Limited to Report Q4, 2024 Results on May 29, 2024

Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director

Price target increased by 9.1% to ₹1,097

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings

Ipca Laboratories Limited to Report Q3, 2024 Results on Feb 14, 2024

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

CFO, MD & Executive Director recently sold ₹22m worth of stock

Price target increased by 9.7% to ₹987

Upcoming dividend of ₹2.00 per share at 0.2% yield

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories Limited to Report Q2, 2024 Results on Nov 10, 2023

Ipca Laboratories Limited Appoints Hitesh Kumar Maheshwari as President R&D (Formulations)

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Ipca Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited to Report Q4, 2023 Results on May 29, 2023

Price target decreased by 7.1% to ₹858

Investor sentiment deteriorates as stock falls 15%

Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet

Consensus EPS estimates fall by 21%

Third quarter 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

Ipca Laboratories Limited (BSE:524494)acquired additional 6.53% stake in Trophic Wellness Pvt. Ltd. for INR 105.8 million.

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Ipca Laboratories Limited Declares Interim Dividend for the Financial Year 2022-23, Payable on December 7, 2022

Ipca Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director

Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director

Insider recently sold ₹1.7m worth of stock

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Ipca Laboratories Limited Approves Interim Dividend as Final Dividend for Financial Year Ended 31St March, 2022

Now 20% undervalued

Ipca Laboratories Limited Announced Demise of Dev Parkash Yadava, Non-Executive and Independent Director

Ipca Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022

Now 20% undervalued after recent price drop

Full year 2022 earnings: EPS misses analyst expectations

Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2022

Now 20% undervalued after recent price drop

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Now 20% undervalued after recent price drop

Price target decreased to ₹1,067

Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Full year 2022 earnings: EPS misses analyst expectations

Insufficient new directors

CFO, Joint MD & Executive Director recently sold ₹21m worth of stock

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?